Browse By: Country ι Category ι Publisher ι Tag

Orphan Drugs in Europe: Pricing, Reimbursement, Funding and Market Access Issues, 2013 Edition

Pages » 208
Published By » JustPharmaReports.com
Price » $2350
In stock
View Report Details
Description

The cost of treating rare disease in an age when austerity measures are hitting total healthcare funding across Europe is a highly controversial, even emotive subject. There is a clear and pressing clinical need, a strong patient voice and the treatments themselves sometimes offer the only hope. But is this enough to assure premium prices and special status in an era of budget limitations, and growing demands for evidence of clinical and cost effectiveness? Payers are becoming increasingly strict. Four of the first seven orphan drugs to enter Germany’s AMNOG procedure were considered to bring only minor additional benefit and for two others the benefit was deemed non-quantifiable.... Click here for more details


Orphan Drugs in Europe: Pricing, Reimbursement, Funding & Market Access Issues, 2011 Edition
The cost of treating rare disease in an age when austerity measures are hitting total healthcare funding across Europe is a highly controversial, even emotive subject. There is a clear and pressing clinical need, a strong patient voice and the treatments themselves sometimes offer the only h
Published Date: Jun 2011
Price: $2300
Market Access Korea: Breaking into the Developed World\'s Fastest Growing Pharmaceutical Market
South Korea as a country has been an economic success story and the origin of much cutting edge technology, but its pharmaceutical market can now also be given ‘Asian tiger’ status. The past four years have seen total sales growth of 15.6%, 13.5%, 12.4% and 13.8% respectively. IMS
Published Date: Nov 2010
Price: $1380
Orphan Drugs in Asia-Pacific: From Designation to Pricing, Funding & Market Access
A major new report Orphan Drugs in Asia-Pacific: From designation to pricing, funding and market access focuses on five developed markets in the region: Japan, South Korea, Taiwan, Singapore and Australia. Each has passed specific measures to promote the development, registration and/or commer
Published Date: Feb 2010
Price: $2320
Biosimilars: Current Situation & Future Prospects, Worldwide
The engine of the biosimilar sector is the same as with small molecule drugs, patent expiry. On this basis, prospects for biosimilars look good, with the vast majority of leading originator brands in the global biologics market expected to lose some degree of protection by 2019. All major countr
Published Date: Mar 2012
Price: $3000
Pharmaceutical Pricing & Distribution in Japan, 2010 Update
The author’s 2008 major title ‘Pharmaceutical Pricing & Distribution in Japan’ was described by PhRMA Japan as ‘a superb report…to understand Japan there is nothing better’. His new report packs all the essentials needed to optimise market access and life
Published Date: Oct 2011
Price: $760
Pharmaceutical Pricing & Distribution in Japan, 2012 Update
No serious pharmaceutical company can afford to ignore Japan, a $120 billion market, the second-largest in the world. It remains a tough and highly competitive market to crack, however, with the environment for developing and marketing medicines dominated by price.  No new bran
Published Date: Jun 2012
Price: $1400
Risk Sharing and Other Forms of Managed Entry Agreements for Medicines, Worldwide
Managed entry agreements apply to an increasing number of new, innovative drugs in a growing number of markets. They are designed to share the risk between the manufacturer and the payer, consequent on uncertainties - usually at launch - about the product’s value (clinical- and cost-effect
Published Date: Feb 2013
Price: $1050
Orphan Drugs in Europe: Pricing, Reimbursement, Funding and Market Access Issues, 2013 Edition
The cost of treating rare disease in an age when austerity measures are hitting total healthcare funding across Europe is a highly controversial, even emotive subject. There is a clear and pressing clinical need, a strong patient voice and the treatments themselves sometimes offer the only hope. B
Published Date: Oct 2013
Price: $2350

 


 

Related News

New Innovations in Optics LED
New innovations in the field of lasers and optics have introduced high density white LED light engines for OEM fiber optic illumination. White light LEDs are rapidly becoming the most preferred source for light guide illumination in several technical applications which were once ruled by HID lamps and tungsten halogen. White LEDs offer operational advantages and substantial cost. LumiBright™ delivers up to 4000 lumens into the light guide. LumiBright have no additional optics and couple
Date: Dec 18

‘Fluctuations in Air Freight Impacts Pharma Supply Chains’
Air freight has been considered to be imperative to the pharmaceutical industry more so as supply chains take on a more complex shape. The Life Science and Pharmaceutical conference held in London on Tuesday stressed upon this very fact. Emerging trends such as healthcare at home, increasing clinical trials across the globe, and advanced therapies as well as companion diagnostics have tremendously changed the pharmaceutical industry, according to David Spillet, key account director at World C
Date: Dec 17

Two AC/DC Drivers Launched by ON
On Semiconductor has recently expanded their product line for NCL3008x by launching two new series of offline AC-DC drivers with Power Factor Correction. Their new line of semiconductors includes the new NCL30085/86/88/30. The NCL30030 widens the existing solutions which support higher power topologies. Their primary purpose would be in high performance LED lighting applications. The new line of PFC drivers are said to be small, robust, and flexible. Three of them use a PF corrected algorithm
Date: Dec 17

Different Prospects of New Nuclear Power
Nuclear energy was once promised as the world’s leading source to provide cheap and safe electrical power. However, The United States has led the way in nuclear research due to government finance and support. Some analysts also claimed that electricity would go meterless in the future.   Nevertheless, things did not turn out as decided due to nuclear waste accumulation, accidents, and safety problems, and most of all – rising costs. Despite these problems, growth in nuclear p
Date: Dec 17

Drop in Oil Prices sets off Alarm Bells in Producers and Shareholders
The well-publicized drop in oil prices this week has been celebrated by the masses all over the world as an answer to years of demands. However, the picture is far from rosy on the other side, as oil exporters and shareholders reacquaint themselves with a sub-$60 per-barrel pricing after a considerable hiatus. Increasing amounts of oil production from countries outside the OPEC (Organization of the Petrol Exporting Countries) is loosening OPEC’s stranglehold over the global petroleum ma
Date: Dec 16

Chinese Construction Shares Rise on Stimulus Bets
For the second consecutive day, China’s stocks have risen, led by railway and construction companies. Their growth has been based on the speculation that the government will take improved steps to support economic growth. China Railway Group Ltd. and China State Construction Engineering Corp. gained more than 7 per cent, enough to lead the rise for infrastructure related companies. Meanwhile, Premier Li Keqiang is visiting Kazakhstan to forge a Silk Road Fund that could finance the buil
Date: Dec 15

Citigroup Charges Investors with US$2.7 Billion for Legal Expenses
Citigroup gave its investors a surprise with its 4th quarter results on Tuesday, with an expected US$2.7 billion legal charge associated with multiple investigations. Citigroup has been discussing for settlement with banking regulators and federal prosecutors over a series of investigations connected to possible manipulation in the lax anti-money-laundering controls and the currency market. The 4th quarter charge also reveals the expected cost of a separate inquiry about the role Citigroup an
Date: Dec 10

After Louisiana-Pacific’s Downgrade - What’s next in the Building and Construction Products Industry?
Louisiana-Pacific Corporation was downgraded by the DA Davidson research firm last Friday from a status of “Buy” to a “Neutral” rating, i.e. LPX 0%. RBC Capital had struck a similar rating a few days earlier. It changed its rating from ‘Sector Perform’ to ‘Underperform’ - where the price target was set as $13.00 per share. These implications apply a downside potential of 22 percent from the present price (as of December 8) of $16.85 per share. 
Date: Dec 09

Southern Company Got Warning from State Monitor on Ga. Nuclear Plant Costs
State monitors has warned Southern Co. that building a multi-billion dollar nuclear plant in Georgia without having a comprehensive construction schedule could cause financial penalties. A report was filed by an analyst and an engineer working for state regulators. They supervise the elevation of two new reactors situated at Plant Vogtle in eastern Georgia. The warning was mentioned in that report. The Public Service Commission has notified for at least two years that Georgia Power, a subs
Date: Dec 08

India to Export Carabeef to Russia
According to some recent talks between India’s (APEDA) and phyto-sanitary watchdog Rosselkhoznadzor, Russia has permitted the imports of buffalo meat (carabeef) from India.  This act falls under the Ministry of Commerce and Industry of India. The move is placed a few days ahead of the Russian President’s visit to India. Rosselkhoznadzor in association with the Ministry of Agriculture of Kazakhstan has involved Indian exporters on its buffalo meat import list.  Compani
Date: Dec 08

Upcoming Reports

Acute Myeloid Leukemia (AML) Therapeutics Market - Global Industry Size, Market Share, Trends, Analysis And Forecasts, 2012 - 2018
Acute myeloid leukemia grows at a fast pace and is found in the blood and bone marrow. The leukemia therapeutics market is divided into four segments namely acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia and chronic myeloid leukemia. In the disease process, imma
Published By: Transparency Market Research
Price: $4795
Antibiotic Market - Global Industry Size, Share, Trends, Analysis And Forecast, 2012 - 2018
An antibiotic is a compound or a substance that fights bacterial infections and kills or slow down their growth. The antibiotic market is witnessing high growth due new product innovations and higher investment in R & D activity. Moreover, the other regulatory concerns to control the antibioti
Published By: Transparency Market Research
Price: $4795
Next Generation Sequencers Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
Next generation sequencers are used inthe sequencing technologies which massively parallelize the DNA sequencing process rather than being limited to single or few fragments of DNA. The next generation sequencing (NGS) technology enables rapid sequencing and produce thousands and millions of seque
Published By: Transparency Market Research
Price: $4795
Rheumatoid Arthritis Pharmacotherapeutics Market - Global Industry Size, Market Share, Trends, Analysis And Forecast, 2012 - 2018
Treatment options for rheumatoid arthritis (RA) are expanding as a result of increasing research activities and more explicit understanding of the pathophysiology of diseases. For the treatment of RA, novel selective inhibitors such as cyclooxygenase-2 (COX-2) are used along with the non-steroidal
Published By: Transparency Market Research
Price: $4795
Prenatal Diagnostics Market - Global Industry Size, Market Share, Trends, Analysis And Forecast, 2012 - 2018
Prenatal diagnostics is a procedure for testing of diseases before the birth of a child, to determine certain inheritable disorders such as chromosome abnormalities, Down’s syndrome, genetic diseases, neural tube defects, and other conditions. It can be conducted by various procedures of scr
Published By: Transparency Market Research
Price: $4795
Pediatric Vaccines Market - Global Industry Analysis, Market Size, Market Share And Forecasts, 2012 - 2018
The global pediatric vaccine market is forecasted to reach $24.3 billion by the year 2017 at a compounded annual growth rate of 11.5 % during 2011-2017. This growth in revenues is expected to be driven by the introduction of new molecules that are currently in regulatory filing stage and those i
Published By: Transparency Market Research
Price: $4795
Dermatological Diagnostics And Therapeutics Market - Global Industry Analysis, Market Size, Market Share And Forecasts, 2012 - 2018
The Dermatological diagnostics and therapeutics market is expected to grow steadily during the forecast period driven by increase in psoriasis market that is expected to boost competition among the existing products with more emerging therapies. Acne is the largest market segment of the dermatolog
Published By: Transparency Market Research
Price: $4795
Hepatitis C Market - Global Industry Size, Share, Trends, Analysis And Forecasts 2012 - 2018
The world market for HCV drugs represents an area of potential opportunities in developed as well as developing countries. Because of the technological advancements and effectiveness, many big market players are focusing on development of innovative drugs for HCV. Major companies are forming coali
Published By: Transparency Market Research
Price: $4795
EPharmacies Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018
The global market for ePharmacies is projected to reach USD 51.75 billion by the end of 2017 owing to the increasing number of tech-savvy people and rising demand for prescription drugs. The ePharmacies meeting the regulatory standards set by the government and following ethical business practices
Published By: Transparency Market Research
Price: $4795
Congestive Heart Failure Treatment Devices Market - Global Industry Size, Share, Trends, Analysis And Forecasts 2012 - 2018
The global market for congestive heart failure treatment devices is expected to reach $5.9 billion by the year 2016 at the compounded annual growth rate of 11.7% during the forecasted period. This growth is mainly attributed by the rising incidences of heart failures across the world. American mar
Published By: Transparency Market Research
Price: $4795